Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

Fashtrades Jan. 9 at 5:21 PM

$RFL .. A squeeze is all i need

0 · Reply

sg44 Jan. 8 at 4:47 PM

$RFL converted traditional IRA shares to Roth. Good luck longs🤞

0 · Reply

GDS_investing Jan. 7 at 3:51 PM

$RFL $SSKN $ZIM $VTVT

0 · Reply

GDS_investing Jan. 7 at 12:14 PM

watch list for today $RFL $SSKN $ZIM $VTVT

0 · Reply

solistocks Jan. 7 at 12:52 AM

$RFL let's get some chatter here. We just hanging tight till may?

3 · Reply

Biotechnicity Jan. 5 at 1:46 AM

$RFL who knows where my last post vanished to but suffice it to say that Express Scripts is refusing to cover MIPLYFFA (arimoclomol). Check out a recent post by @HuntingHighAndLow on the ZVRA board. Opening for Cyclo?

0 · Reply

RemitTekram Jan. 2 at 3:37 PM

$RFL Halt to 7pt?!?!?

0 · Reply

Love_To_Learn Jan. 2 at 12:41 PM

$BVC fusing 1.44 with 1.52 super filler of $RFL *

0 · Reply

GDS_investing Dec. 31 at 7:52 PM

$VTVT $ZIM $RFL $AGEN $SSKN

0 · Reply

GDS_investing Dec. 31 at 6:44 PM

$RFL add more today this price is a gift imo. tax loss harvesting is over time for huge reversal 10$ next year fda imo long

1 · Reply

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Oct 29, 2025, 4:24 PM EDT - 2 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 2 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Sep 16, 2025, 8:00 AM EDT - 4 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Jun 11, 2025, 7:00 AM EDT - 7 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 7 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 8 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 8 months ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 9 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 9 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 10 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 10 months ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 11 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Fashtrades Jan. 9 at 5:21 PM

$RFL .. A squeeze is all i need

0 · Reply

sg44 Jan. 8 at 4:47 PM

$RFL converted traditional IRA shares to Roth. Good luck longs🤞

0 · Reply

GDS_investing Jan. 7 at 3:51 PM

$RFL $SSKN $ZIM $VTVT

0 · Reply

GDS_investing Jan. 7 at 12:14 PM

watch list for today $RFL $SSKN $ZIM $VTVT

0 · Reply

solistocks Jan. 7 at 12:52 AM

$RFL let's get some chatter here. We just hanging tight till may?

3 · Reply

Biotechnicity Jan. 5 at 1:46 AM

0 · Reply

RemitTekram Jan. 2 at 3:37 PM

$RFL Halt to 7pt?!?!?

0 · Reply

Love_To_Learn Jan. 2 at 12:41 PM

$BVC fusing 1.44 with 1.52 super filler of $RFL *

0 · Reply

GDS_investing Dec. 31 at 7:52 PM

$VTVT $ZIM $RFL $AGEN $SSKN

0 · Reply

GDS_investing Dec. 31 at 6:44 PM

$RFL add more today this price is a gift imo. tax loss harvesting is over time for huge reversal 10$ next year fda imo long

1 · Reply

Love_To_Learn Dec. 31 at 6:23 PM

$SGBX GIVING U OLD BELOVED PSTV MOVEMENT NOW OFF 1.95 1.91 ETC WHILE SHE IS NOW TEMP CYTX* $PSTV PRE RS SGBX 0.09-0.50 YEARS AGO ON SGBX USING YOUR X TO GAIN ACCESS WITH CYTX CURRENTLY 20:1 RATIO RS ADDING HOLES ON 0.09/0.5/0.09-0.5 FOR MARKET COVERAGE ALSO 0.50* BYPASS FOR MARKETS SWAPPING OUT CONVERTING RS RATIO SGBX 20:1 = 1.8-10 PT FOR MARKETS ALSO USING $OTLK MANIPULATION JOB ACCESSING USIGN T FROM OUR CYTX AND OTLK 2 T'S BOTH IN 2ND POSITION OTLK CYTX MERGING WITH OLD CYT(H) 0.62* NOW $RFL

0 · Reply

OfficialStocktwitsUser Dec. 29 at 8:45 PM

$RFL RSI: 37.68, MACD: -0.0307 Vol: 0.12, MA20: 1.28, MA50: 1.29 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Love_To_Learn Dec. 29 at 6:17 PM

$RFL borrowing your f 1.17 anomaly all F symbols mobilizing using beloved as its only sun !

0 · Reply

Tradetime3472 Dec. 29 at 4:18 PM

$RFL anything about Alzheimer’s?

1 · Reply

Love_To_Learn Dec. 29 at 12:05 PM

$RFL forwarding update date * by 4 days sooner than expected

0 · Reply

SuperGreenToday Dec. 27 at 12:21 AM

$RFL Share Price: $1.20 Contract Selected: May 15, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.09 Potential Upside: 71% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Biotechnicity Dec. 24 at 5:38 PM

$RFL oof

0 · Reply

GDS_investing Dec. 23 at 4:02 PM

$RFL AWESOME !

1 · Reply

Love_To_Learn Dec. 23 at 1:19 PM

$MDAI $RFL partial pivot *

0 · Reply

Love_To_Learn Dec. 22 at 9:31 PM

$HCTI LIL MOVE OFF 1.49 * MAKING THE 1.52 SUPER FILLER OF $RFL ONLINE AS WELL ALL SYSTEMS GO FOR TOMO PANDORA MOVEMENT